Drugs / 177Lu-EB-FAPI
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05400967 | Jan 2022 → Jan 2025 overdue | — | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06081322 | Sep 2023 → Jun 2024 | digestive system carcinoma | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-EB-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05400967 ↗ |
| Modality | Other / unclassified | “177Lu therapeutic drug modified by Evans Blue (EB)” NCT05400967 ↗ |
| Route | Intravenous | “177Lu-EB-FAPI was injected intravenously for therapy” NCT05400967 ↗ |